Madrigal Pharmaceuticals, Inc. Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Madrigal Pharmaceuticals, Inc.Headquarters: West Conshohocken, 
                        PA, United States
                    
Employees: 71
CEO: Dr. Paul A. Friedman M.D.

                                    NASDAQ: MDGL
                                
                                            -4.22%
                                            
Market Cap$7.42 Billion

                        USD as of Jan. 1, 2025
                    
                            Market Cap History

Madrigal Pharmaceuticals, Inc. Categories

United States Healthcare Biotechnology
United States Healthcare United States Biotechnology

Madrigal Pharmaceuticals, Inc. market capitalization over time

Evolution of Madrigal Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Madrigal Pharmaceuticals, Inc.

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$622.07 B
Vertex Pharmaceuticals Incorporated	$113.24 B
CSL Limited	$95.75 B
Regeneron Pharmaceuticals, Inc.	$76.33 B
Marinomed Biotech AG	$56.13 B

Sector:

Company	Market Cap (USD)
Lilly	$689.42 B
Novo Nordisk	$622.07 B
UnitedHealth Group	$487.54 B
Johnson & Johnson	$353.05 B
AbbVie	$301.60 B

Detailed Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-à agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date	Sept. 30, 2024
Revenue TTM	$76.8 M
EBITDA	$-547,180,032
Gross Profit TTM	$74.0 M
Profit Margin	0.00%
Operating Margin	-187.06%
Quarterly Revenue Growth	324.75%